Neurim’s claim for additional damages survives in Circadin patent case

Intellectual Property 2024-06-03 11:48 pm By Sam Matthews | Melbourne

A judge has upheld Neurim Pharmaceutical’s claim for additional damages against two generic drug companies found to have infringed its patent for insomnia drug Circadin, despite the company’s failure to comply with an earlier ruling.